Evidence
June 1, 2023Population Health Article / Publication
Despite Medicare making strides toward improving access with expanded coverage criteria in recent years, experts in the field of endocrinology are speaking out on the importance of reaching underserved populations with the “potentially life-changing benefits” of CGM technology. In addition to expanded coverage eligibility, Richard M. Bergenstal, MD, noted that access to CGM must be simplified by making the technology more readily available in clinic and community settings. To support these efforts, Irl B. Hirsch, MD, called on the role of patient and provider education for driving appropriate uptake and utilization. Managed care and payer professionals will find these expert insights valuable for addressing disparities in diabetes care and outcomes among members affected by SDOH.
Learn MoreMay 29, 2023Clinical Outcomes Article / PublicationLearn MoreMay 24, 2023Coverage and Benefit Design Article / PublicationLearn More
HbA1c Improvements After Initiation of Real-Time Continuous Glucose Monitoring in Primary Care Patients With Type 2 Diabetes
May 11, 2023Clinical Outcomes Article / PublicationLearn MoreReviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
May 4, 2023Clinical Outcomes Webinar / Archive
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreReal-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Despite Medicare making strides toward improving access with expanded coverage criteria in recent years, experts in the field of endocrinology are speaking out on the importance of reaching underserved populations with the “potentially life-changing benefits” of CGM technology. In addition to expanded coverage eligibility, Richard M. Bergenstal, MD, noted that access to CGM must be simplified by making the technology more readily available in clinic and community settings. To support these efforts, Irl B. Hirsch, MD, called on the role of patient and provider education for driving appropriate uptake and utilization. Managed care and payer professionals will find these expert insights valuable for addressing disparities in diabetes care and outcomes among members affected by SDOH.
Learn MoreMay 29, 2023Clinical Outcomes Article / PublicationLearn MoreMay 24, 2023Coverage and Benefit Design Article / PublicationLearn MoreHbA1c Improvements After Initiation of Real-Time Continuous Glucose Monitoring in Primary Care Patients With Type 2 Diabetes
May 11, 2023Clinical Outcomes Article / PublicationLearn MoreReviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
May 4, 2023Clinical Outcomes Webinar / Archive
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreReal-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
May 24, 2023Coverage and Benefit Design Article / PublicationLearn MoreHbA1c Improvements After Initiation of Real-Time Continuous Glucose Monitoring in Primary Care Patients With Type 2 Diabetes
May 11, 2023Clinical Outcomes Article / PublicationLearn MoreReviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
May 4, 2023Clinical Outcomes Webinar / Archive
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreReal-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
HbA1c Improvements After Initiation of Real-Time Continuous Glucose Monitoring in Primary Care Patients With Type 2 Diabetes
May 11, 2023Clinical Outcomes Article / PublicationLearn MoreReviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
May 4, 2023Clinical Outcomes Webinar / Archive
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreReal-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
HbA1c Improvements After Initiation of Real-Time Continuous Glucose Monitoring in Primary Care Patients With Type 2 Diabetes
Reviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
May 4, 2023Clinical Outcomes Webinar / Archive
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreReal-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Reviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreReal-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreMarch 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
March 17, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MorePayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
March 2, 2023Population Health CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE Expired
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
PayerTalkCE Presents: Real-time Continuous Glucose Monitoring Impact on Glycemic Control and Acute Metabolic Events
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click here to review- CE ExpiredEducational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical outcomes of real-time continuous glucose monitoring initiation in insulin-treated patients with diabetes
- Access health plan opportunities to improve diabetes outcomes for patients with diabetes based on current treatment guidelines and quality measures
- Identify how multi-disciplinary care teams can support quality improvement interventions for patients with diabetes
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.